DDDR-31. THE CHEMOTHERAPEUTIC ACTIVITY OF TEMOZOLOMIDE IS ANTAGONIZED BY ITS HYDROLYSIS PRODUCT, AIC
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae165.0516
Abstract: Temozolomide is the only FDA-approved drug that has demonstrated improved overall survival in patients with Glioblastoma. Despite the clinical impact it has had, overall survival today largely remains less than two years with current standard-of-care.… read more here.
Keywords: antagonized hydrolysis; aic; hydrolysis product; activity ... See more keywords